About the Company:
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. Our focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors.Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
Eris Lifescience develops, manufacture and commercialize branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Company’s focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.
The chronic category of the IPM contributed 64.2% of the revenues in Fiscal 2016 and 65.4% of the revenues for the six months ended September 30, 2016
Eris was ranked 21st out of 353 domestic and multinational companies present in the chronic category of the IPM, in terms of revenues for Fiscal 2016.
Eris is one of the fastest growing company, in the chronic category, among the top 25 companies in terms of revenues, with revenue growth at CAGR of 33.9%, between Fiscals 2012 and 2016 .
Company’s product portfolio is primarily focused on therapeutic areas which require the intervention of specialists and super specialists such as cardiologists,diabetologists, endocrinologists and gastroenterologists. Sales in metro cities and class 1 towns, together accounted for 75.7% of our revenues in Fiscal 2016 and 77.6% for the six months ended September 30, 2016, as a majority ofspecialists and super specialists are based in these metro cities and class 1 towns.
Company owns and operates a manufacturing facility in Guwahati, Assam.They also outsource the manufacturing of certain products, and currently use approximately 20 third party manufacturers.They have developed capabilities in the commercialization of pharmaceutical products including sales, marketing, quality assurance,distribution, compliance and regulatory aspects. They have strong sales, marketing and distribution capabilities in India with
seven sales divisions focused on developing and growing engagement with specialists and super specialists. Company’s sales divisions is also responsible for commercialization and marketing strategy.
Promoters have an average experience of over a decade in the pharmaceuticals industry. In addition, company is led by a well- qualified and experienced management team, which has believe has demonstrated its ability to manage and grow the operations, and has substantial experience in pharmaceutical sales and marketing. Company hasreceived the ‘Competitive Strategy Leadership’ award for 2013, from Frost & Sullivan and our Promoter, Chairman and Managing Director.
TOP Shareholders:
| Sr.No. | Shareholder Name | Number of Equity Shares held | Percentage of Equity Share Capital % |
|---|---|---|---|
| 1. | Amit Indubhushan Bakshi | 54,959,000 | 39.97 |
| 2. | Bhikhabhai Chimanlal Shah | 12,429,000 | 9.04 |
| 3. | Rakeshbhai Bhikhabhai Shah | 15,854,000 | 11.53 |
| 4. | Botticelli | 22,344,000 | 16.25 |
| 5. | Himanshu Jayantbhai Shah | 6,972,000 | 5.07 |
| 6. | Inderjeet Singh Negi | 6,971,000 | 5.07 |
| 7. | Rajendrakumar Rambhai Patel | 6,971,000 | 5.07 |
| 8. | Kaushal Kamlesh Shah | 5,500,000 | 4.00 |
| 9. | Hetal Rasiklal Shah | 5,500,000 | 4.00 |
| Total | 137,500,000 | 100% |
Company’s Strengths:
- Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders.
- One of the fastest growing companies in certain high growth therapeutic areas with a portfolio of
complementary products. - Portfolio of high volume and leading brands.
- Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and
concentration of specialists and super specialists. - Strong sales, marketing and distribution capabilities.
Future Growth Strategies of the Company:
- Consolidate company’s position in therapeutic areas in which they have significant presence.
- Target and enhance company’s presence in large and high-growth therapeutic areas.
- Explore in-licensing and co-development opportunities to leverage company’s sales, marketing and distribution and
manufacturing infrastructure. - Target future patent expires in India.
- Enhance the product line and expand the capabilities through strategic acquisitions.
Positives for the Company:
- Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders.
- One of the fastest growing companies in certain high growth therapeutic areas with a portfolio of
complementary products. - Portfolio of high volume and leading brands.
- Focus on Metro Cities and Class 1 towns in India which have higher incidence of lifestyle disorders and
concentration of specialists and super specialists. - Multi-faceted product selection and engagement model leading to growth in prescription for our products.
- Strong sales, marketing and distribution capabilities.
Company’s Management Team:
- Mr. Amit Indubhushan Bakshi (Designation: Chairman and Managing Director)
- Mr. Himanshu Jayantbhai Shah (Designation: Executive Director)
- Mr. Inderjeet Singh Negi (Designation: Executive Director)
Financials of the Company:
| (in Crores) | FY 12 | FY 13 | FY 14 | FY 15 | FY 16 | 31st Sept FY 17 |
|---|---|---|---|---|---|---|
| Revenue | 273.94 | 393.06 | 508.80 | 545.55 | 597.02 | 370.79 |
| Net Profit | 37.06 | 58.44 | 70.79 | 89.25 | 134.85 | 130 |
